For generations, Indian consumers have equated higher medicine prices with superior quality, often shelling out premiums for branded drugs at pharmacies. A pioneering citizen-led study, the Citizen-Generic vs Branded Drugs Quality Project, shatters this belief. Launched by Kerala-based non-profit Mission for Ethics and Science in Healthcare, the initiative involved doctors, scientists, and volunteers collecting real-world samples from markets across India. Laboratory tests on these samples demonstrate that widely prescribed generic medicines perform identically to their far costlier branded equivalents, prompting urgent questions about affordability, physician prescribing habits, and market distortions.
This independent effort addresses a critical gap in public trust. India, dubbed the "pharmacy of the world," exports generics worth over $25 billion annually—supplying nearly 20% of global demand—yet domestic skepticism persists. Factors like aggressive marketing by pharmaceutical companies, physician incentives, and historical quality lapses in unregulated segments have fueled this bias.
Also Read: Deadly Drug-Resistant Fungus Candida auris Spreading Worldwide: Indian Study Reveals
Study Design and Rigorous Testing Protocol
The study targeted 22 essential drugs for prevalent conditions: diabetes (e.g., metformin), heart disease (e.g., atorvastatin), gastric disorders (e.g., pantoprazole), infections (e.g., antibiotics), and chronic liver ailments (e.g., rifaximin). Researchers gathered 131 samples, categorized as top-selling branded medicines from multinationals like Pfizer or Abbott, branded generics, local trade generics, and government-supplied options under Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP).
Testing occurred at a NABL- and US FDA-accredited lab, evaluating each sample against five Indian Pharmacopoeia (IP) standards: drug content (90-110% potency), impurity levels (<0.5%), dissolution="" rate="" (="">80% in 30 minutes for tablets), physical characteristics, and uniformity. Results were unequivocal: 100% of generics met or exceeded benchmarks, showing no quality deficits versus brands. For instance, all rifaximin samples dissolved uniformly within IP limits, ensuring equivalent bioavailability.
Stark Price Disparities Exposed
Led by hepatologist Dr. Cyriac Abby Philips (known online as "The Liver Doc"), the study quantified pricing inequities. Despite identical active ingredients and quality, branded drugs averaged Rs 11.17 per tablet—over 4x the Rs 2.4 for Jan Aushadhi versions. For pantoprazole, branded prices hit Rs 12.50 per tablet versus Rs 2.00 generics (6.25x markup); atorvastatin reached Rs 18.00 against Rs 3.50 (5.14x); and rifaximin soared to Rs 45.00 versus Rs 3.20 (14x). These gaps arise from branding, marketing (20-30% of costs), and distribution markups, not superior manufacturing.
Real-World Impact: A Patient's Tragic Story
Dr. Philips shared a poignant case: a cirrhosis patient prescribed rifaximin for hepatic encephalopathy. The branded version cost Rs 45 per tablet; the patient afforded only 15 days' supply. He returned in liver coma, incurring Rs 80,000 in ICU bills—money borrowed from neighbors. Reflecting publicly on X, Dr. Philips admitted his own hesitation: "I was unsure about non-promoted generics and feared backlash if issues arose." This anecdote underscores how bias leads to rationing, non-adherence, and worsened outcomes. In India, where 62-69% of healthcare is out-of-pocket and drugs claim 50-70% of expenses, such practices exacerbate inequality.
Barriers to Trust and Pathways Forward
Physician distrust stems from past incidents—like 2018 substandard cough syrup exports—and pharma influence via free samples or conferences. International studies (e.g., US FDA data on overseas generics) note occasional issues, but this study's pharmacopoeial rigor counters them.
Policy responses are accelerating: States like Tamil Nadu and Rajasthan mandate generic prescribing in public hospitals. The central government aims for 25,000 Jan Aushadhi stores by 2025, with drugs 50-90% cheaper. Experts urge bioequivalence mandates, transparent labeling, and education campaigns. As Dr. Philips asserts, "The molecule matters, not the marketing."
This study doesn't claim all generics are flawless—ongoing vigilance is essential—but it proves affordable options deliver equal efficacy, potentially saving households billions while boosting adherence.
Also Read: Fresh Snowfall Halts Leh Flights as Cold Wave Tightens Grip on Kashmir